🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Mitral Annular Repair With the CathHELIX™ Transcatheter System in Subjects With FMR

RecruitingNAAges 18 Years - anyAllHVR Cardio Oy
NCT07188233 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Patients with functional mitral regurgitation classified as moderate to severe (3+) or severe (4+) that are symptomatic (NYHA Class II-IV) will be evaluated for treatment using the CathHELIX Transcatheter Mitral Annuloplasty System.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Moderate to severe (3+) or severe (4+) functional mitral regurgitation * Left ventricular ejection fraction ≥30% * Symptomatic New York Heart Association (NYHA) Class II to IV). Exclusion Criteria: * Oxygen dependent for COPD * Active or suspected endocarditis * Severe symptomatic carotid stenosis * Has undergone heart transplantation. * Severe calcification of the mitral annulus or leaflets * Coronary sinus anatomy that may preclude proper treatment with the device
💊

What it tests

  • Transcatheter Mitral Valve Repair
📍

Where

2 sites
Tbilisi Heart and Vascular Clinic
Tbilisi, Georgia
Vilnius University Hospital, Santaros Klinikos, Public Institution
Vilnius, Lithuania
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy